AU2929897A - Polypeptide conjugates for transporting substances across cell membranes - Google Patents

Polypeptide conjugates for transporting substances across cell membranes

Info

Publication number
AU2929897A
AU2929897A AU29298/97A AU2929897A AU2929897A AU 2929897 A AU2929897 A AU 2929897A AU 29298/97 A AU29298/97 A AU 29298/97A AU 2929897 A AU2929897 A AU 2929897A AU 2929897 A AU2929897 A AU 2929897A
Authority
AU
Australia
Prior art keywords
cell membranes
polypeptide conjugates
transporting substances
transporting
substances
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU29298/97A
Other versions
AU729643B2 (en
Inventor
James E Summerton
Dwight D Weller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sarepta Therapeutics Inc
Original Assignee
Antivirals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antivirals Inc filed Critical Antivirals Inc
Publication of AU2929897A publication Critical patent/AU2929897A/en
Application granted granted Critical
Publication of AU729643B2 publication Critical patent/AU729643B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU29298/97A 1996-05-01 1997-04-30 Polypeptide conjugates for transporting substances across cell membranes Ceased AU729643B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1634796P 1996-05-01 1996-05-01
US60/016347 1996-05-01
US2860996P 1996-10-23 1996-10-23
US60/028609 1996-10-23
PCT/US1997/007335 WO1997040854A2 (en) 1996-05-01 1997-04-30 Polypeptide conjugates for transporting substances across cell membranes

Publications (2)

Publication Number Publication Date
AU2929897A true AU2929897A (en) 1997-11-19
AU729643B2 AU729643B2 (en) 2001-02-08

Family

ID=26688485

Family Applications (1)

Application Number Title Priority Date Filing Date
AU29298/97A Ceased AU729643B2 (en) 1996-05-01 1997-04-30 Polypeptide conjugates for transporting substances across cell membranes

Country Status (5)

Country Link
EP (1) EP0966303A2 (en)
JP (1) JP2000509394A (en)
AU (1) AU729643B2 (en)
CA (1) CA2252706A1 (en)
WO (1) WO1997040854A2 (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001509167A (en) * 1997-01-24 2001-07-10 エイブイアイ バイオファーマ，インコーポレイテッド H. Methods and conjugates for treating pylori infection
US6455495B1 (en) * 1997-02-14 2002-09-24 The Salk Institute For Biological Studies Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
EP0975370B9 (en) 1997-05-21 2004-11-03 The Board Of Trustees Of The Leland Stanford Junior University Composition and method for enhancing transport across biological membranes
US20020064520A1 (en) * 1999-08-19 2002-05-30 Yanina Rozenberg Targeted artificial gene delivery
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6593292B1 (en) 1999-08-24 2003-07-15 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6730293B1 (en) 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
WO2002004479A1 (en) 2000-07-06 2002-01-17 Avi Biopharma, Inc. TRANSFORMING GROWTH FACTOR BETA (TGF-β) BLOCKING AGENT-TREATED STEM CELL COMPOSITION AND METHOD
WO2002007773A2 (en) 2000-07-21 2002-01-31 Essentia Biosystems, Inc. Multi-component biological transport systems
JP2004523480A (en) * 2000-08-22 2004-08-05 ニュー リバー ファーマシューティカルズ， インコーポレイテッド Active agent delivery systems and methods of protecting and administering active agents
JP2006516948A (en) * 2000-11-14 2006-07-13 ニュー リバー ファーマシューティカルズ インコーポレイテッド New drug compound containing abacavir sulfate and method for producing and using the compound
IL163666A0 (en) * 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
WO2004060403A2 (en) 2003-01-06 2004-07-22 Angiochem Inc. Aprotinin and anglos as carriers across the blood-brain barrier
US20050234002A1 (en) 2004-01-23 2005-10-20 Mourich Dan V Antisense oligomers and methods for inducing immune tolerance and immunosuppression
US8092788B2 (en) 2004-03-03 2012-01-10 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
CA2571593C (en) 2004-07-02 2015-04-21 Avi Biopharma, Inc. Antisense antibacterial method and compound
CA2596506C (en) 2005-02-09 2021-04-06 Avi Biopharma, Inc. Antisense composition and method for treating muscle atrophy
US7557182B2 (en) 2005-02-18 2009-07-07 Angiochem Inc. Molecules for transporting a compound across the blood-brain barrier
BRPI0608249A2 (en) 2005-03-03 2009-12-08 Revance Therapeutics Inc formulation, method for topical application and kit for transdermal botulinum toxin delivery
ES2362301T3 (en) 2005-03-03 2011-07-01 Revance Therapeutics, Inc. COMPOSITIONS AND PROCEDURES FOR TOPICAL APPLICATIONS AND TRANSDERMAL RELEASE OF AN OLIGOPEPTIDE.
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
AU2006267051B2 (en) 2005-07-13 2013-03-07 Sarepta Therapeutics, Inc. Antisense antibacterial method and compound
PT2233156E (en) 2005-07-15 2013-07-31 Angiochem Inc Use of aprotinin polypeptides as carriers in pharmaceutical conjugates
US8501704B2 (en) 2005-11-08 2013-08-06 Sarepta Therapeutics, Inc. Immunosuppression compound and treatment method
EP1935434A1 (en) * 2006-12-19 2008-06-25 Novosom AG Construction and use of transfection enhancer elements
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
ES2665017T3 (en) 2008-03-20 2018-04-24 University Of Florida Research Foundation, Inc. Improve the potential for return and repair of stem cells in vascular lesions
EP2143726A1 (en) * 2008-07-11 2010-01-13 Novosom AG Nucleic acid comprising zwitterionic nucleotides
AU2009304560A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of GLP-1 agonists and uses thereof
BRPI0922689A2 (en) 2008-12-05 2018-11-06 Angiochem Inc. neurotensin conjugates or neurotensin analogs and uses thereof
AU2009335740B2 (en) * 2008-12-17 2016-04-21 Sarepta Therapeutics, Inc. Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
MX2011011023A (en) 2009-04-20 2012-01-20 Angiochem Inc Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog.
WO2010141845A2 (en) 2009-06-05 2010-12-09 13Therapeutics, Inc. Immunoregulatory peptides and methods of use
US9161988B2 (en) 2009-07-02 2015-10-20 Angiochem Inc. Multimeric peptide conjugates and uses thereof
KR102095478B1 (en) 2010-05-28 2020-04-01 사렙타 쎄러퓨틱스, 인코퍼레이티드 Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
US10017763B2 (en) 2010-09-03 2018-07-10 Sarepta Therapeutics, Inc. dsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups
US8580748B2 (en) 2011-04-06 2013-11-12 13Therapeutics, Inc. Peptides for the treatment of hearing
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
KR20210081448A (en) 2011-11-18 2021-07-01 사렙타 쎄러퓨틱스, 인코퍼레이티드 Functionally-modified oligonucleotides and subunits thereof
EP2828395B1 (en) 2012-03-20 2018-10-24 Sarepta Therapeutics, Inc. Boronic acid conjugates of oligonucleotide analogues
GB201210358D0 (en) * 2012-06-12 2012-07-25 Polytherics Ltd Complexes
CN104781276A (en) 2012-08-14 2015-07-15 安吉奥开米公司 Peptide-dendrimer conjugates and uses thereof
MA41795A (en) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc EXCLUSION OF AN EXON INDUCED BY ANTISENSE COMPOUNDS IN MYOSTATIN
US11020417B2 (en) 2015-06-04 2021-06-01 Sarepta Therapeutics, Inc Methods and compounds for treatment of lymphocyte-related diseases and conditions
JP6823055B2 (en) 2015-06-15 2021-01-27 アンジオケム インコーポレーテッド How to treat soft meningeal carcinomatosis
EP3377067A4 (en) * 2015-10-07 2019-07-31 Cormedix Inc. Skin-penetrating formulation of taurolidine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1541436A (en) * 1976-02-02 1979-02-28 Searle & Co Immunological materials
GB9017024D0 (en) * 1990-08-03 1990-09-19 Erba Carlo Spa New linker for bioactive agents
GB9026491D0 (en) * 1990-12-05 1991-01-23 Erba Carlo Spa Anthracycline-conjugates
ES2448467T3 (en) * 1996-03-12 2014-03-14 Pg-Txl Company, L.P. Water soluble prodrugs

Also Published As

Publication number Publication date
WO1997040854A2 (en) 1997-11-06
WO1997040854A3 (en) 1998-03-12
EP0966303A2 (en) 1999-12-29
JP2000509394A (en) 2000-07-25
CA2252706A1 (en) 1997-11-06
AU729643B2 (en) 2001-02-08

Similar Documents

Publication Publication Date Title
AU2929897A (en) Polypeptide conjugates for transporting substances across cell membranes
AU4756297A (en) Very thin microporous material
AU4322797A (en) Protruding case for mail
AU7850898A (en) Stabilized electrochemical cell
AU4864497A (en) Closure membrane
AU4922497A (en) Interleukin-18-receptor proteins
AUPO044396A0 (en) Improvements in containers
AUPO777997A0 (en) Improvements in containers
AU1606800A (en) Membrane transport proteins
AU3169497A (en) Closure membrane
AU4257596A (en) Peptides and synthetic cell membranes
AU2348197A (en) Geocomposite membrane
AU2300697A (en) Improved membrane
AU4635593A (en) Vesicle membrane transport proteins
AU6912594A (en) Neurotransmitter transporter
AUPO965097A0 (en) Improvements in containers
IL129945A0 (en) Enhanced transport with a plastid membrane transport protein
AUPO957397A0 (en) Transporter protein
AU5860998A (en) Cell for filling coverlets or the like
AU6634298A (en) Biosensor for cells
AU1515997A (en) Supports for reinforcement materials
AU1450897A (en) Handling materials
AU7362398A (en) B cell receptor associated proteins
AU1877697A (en) Electrochemical cell
AU2483997A (en) Transport container improvements

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)